|
Aratana shares
jumped 21 percent in extended trading on Friday.
The study showed that an oral 3 mg/kg dose of the drug, AT-002,
given daily for four days significantly increased appetite in
dogs, compared with those on placebo.
The company said it plans to submit the results to the U.S. Food
and Drug Administration as it seeks marketing approval, and
expects to start commercializing the drug in 2016.
The company's pipeline includes a string of experimental drugs
for pets with serious medical illness such as cancer, viral
diseases and allergies.
The Kansas City-based company's shares were trading at $16.25
after the bell.
(Reporting By Samantha Kareen Nair in Bengaluru; Editing by
Joyjeet Das)
[© 2015 Thomson Reuters. All rights
reserved.] Copyright 2015 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
|
|
